Janssen Research & Development

130 articles about Janssen Research & Development

• MorphoSys' Licensee Janssen Receives CHMP Positive Opinion for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA) in the European Union (EU)

  10/19/2020

  MorphoSys AG announced that its licensee Janssen Research & Development, LLC. has announced it received a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency recommending the expanded use of Tremfya for the treatment of adult patients with active psoriatic arthritis in the European Union.

• MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis

  6/14/2019

  MorphoSys AG announced that its licensee Janssen Research & Development, LLC, reported top-line results from the phase 3 DISCOVER 1 and 2 studies in a press release issued.

• nference Enters into an R&D Data Science Strategic Partnership with Janssen

  6/10/2019

  Multi-year research collaboration and software agreement reimagines the discovery and clinical development of medicines through data sciences

• DARZALEX® (daratumumab) Investigational Study Shows Increased Depth of Response and Longer Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who are Eligible for a Transplant

  6/2/2019

  The Phase 3 CASSIOPEIA study is one of the largest transplant studies ever conducted in multiple myeloma, and the largest study conducted with DARZALEX

• UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen

  4/23/2019

  Focused Agreement is on Therapeutic Area of Mutual Interest

• MorphoSys Announces that its Licensee Janssen has Expanded Clinical Development of Guselkumab (Tremfya(R)) into Familial Adenomatous Polyposis

  4/15/2019

  MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab) into familial adenomatous polyposis, a disease of the gastrointestinal tract.

• One Mind Announces Request for Proposals for Five New $250,000 Rising Star Research Awards

  3/25/2019

  Given the growing challenges of addressing brain illness and injury, One Mind, in collaboration with Janssen Research & Development LLC, Otsuka Pharmaceuticals, Kaiser Permanente, the Gifford Foundation, and Bettina Bryant, is offering up to five Rising Star Research Awards in 2019.

• Dr. Guislain Museum and Janssen Seek Global Nominations for Annual "Breaking the Chains of Stigma" Award

  2/28/2019

  The Dr. Guislain Museum and Janssen Research & Development, LLC, today announced the global nominations for the Dr. Guislain "Breaking the Chains of Stigma" Award can now be submitted at www.drguislainaward.org until 14 April, 2019.

• MorphoSys Announces that its Licensee Janssen Has Received U.S. FDA Approval for Tremfya(R) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

  2/27/2019

  MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has reported that the U.S. Food and Drug Administration has approved Tremfya One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis.

• 

  J&J’s Esketamine Clears Advisory Panel Hurdle for Depression Treatment

  2/13/2019

  On Tuesday, a U.S. Food and Drug Administration advisory panel overwhelmingly supported approval of the nasal spray treatment.
• 

  Johnson & Johnson's Potential Depression Blockbuster Esketamine Shows Promise in Phase II Study

  12/29/2017

  The drug showed a significant, clinically meaningful and fast-acting improvement in depression symptoms compared to an intranasal placebo.

• Janssen R&D Establishes First-Of-Its-Kind Mobile Medication And Data Management Technology Platform For Industry Use

  10/11/2017

• Janssen R&D Submits New Drug Application To FDA For The First Darunavir-Based Single Tablet Regimen For The Treatment Of HIV-1

  9/25/2017

• Janssen R&D Release: New Two-Year TREMFYA (guselkumab) Data Show Patients With Moderate To Severe Plaque Psoriasis Achieved Consistent Rates Of Skin Clearance

  9/18/2017

• Janssen R&D Release: U.S. FDA Grants Priority Review Of XARELTO (Rivaroxaban) sNDA For A 10 Mg Dose To Reduce The Risk Of Recurrent Venous Thromboembolism (VTE)

  6/28/2017

• Janssen R&D Release: Data At ASCO Show Consistent Progression-Free Survival Benefit In Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients Treated With Ibrutinib, Including Those With High-Risk Disease, With Up To Four Yea

  6/5/2017

• Janssen R&D Release: Daratumumab Combination Therapy Improved Clinical Outcomes Regardless Of Cytogenetic Risk For Previously-Treated Patients With Multiple Myeloma

  6/5/2017

• MorphoSys AG Announces That Its Licensee Janssen R&D Reported Updates On The Development Of Guselkumab

  5/24/2017

• Janssen R&D Submits Supplemental New Drug Application To U.S. FDA Based On EINSTEIN CHOICE Data, Which Showed Superiority With XARELTO (Rivaroxaban) Versus Aspirin In Reducing Risk Of Recurrent Venous Thromboembolism (VTE), With Low Rates Of Major Bleedin

  5/1/2017

• The Castleman Disease Collaborative Network Announces A Research Collaboration With Janssen R&D To Conduct A Proteomics Study Of Idiopathic Multicentric Castleman Disease

  4/12/2017